SELL and acute myeloid leukemia: Previous chemotherapies induced lymphopenia in the blood of the B-NHL and AML patients (B-NHL, n=8, median 0.63x10e6 CD3+/μl, AML, n=10, median 1.3x10e6 CD3+/μl) and reduced the percentage of Tscm-like lymphocytes (CD45RA+CD62L+) which critically reduced the outcome of CAR-T manufacturing.